Merck to End Development of Two Cancer Candidates: Time to Sell?
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider ...
lifesciencesweden.se16h
MSD discontinues development of cancer drugs after trial failures
American Merck & Co, known in Europe as MSD, has discontinued the development of vibostolimab and favezelimab, two ...
The Pharma Letter17h
Merck & Co cuts TIGIT and LAG-3 programs
US pharma giant Merck & Co has announced the discontinuation of the clinical development programs for vibostolimab, an ...
Daily20h
Merck discontinues clinical development programs for vibostolimab, favezelimab
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical ...
Pharmabiz20h
Merck to discontinue phase 3 KeyVibe-003 & KeyVibe-007 trials of vibostolimab and favezelimab FDCs with pembrolizumab in certain patients with NSCLC
Merck, known as MSD outside of the United States and Canada, announced the discontinuation of the clinical development programmes for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG ...